Log in

Lifesci Capital Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Lifesci Capital. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Lifesci Capital.

CompanyDateActionBrokerageRatingPrice TargetImpact on PriceActions
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
11/17/2020Reiterated byLifesci CapitalOutperformHigh    
BLU
BELLUS Health Inc. (BLU.TO)
11/12/2020Reiterated byLifesci CapitalOutperformN/A    
BLU
BELLUS Health
11/12/2020Reiterated byLifesci CapitalOutperformMedium    
TARS
Tarsus Pharmaceuticals
11/10/2020Reiterated byLifesci CapitalOutperformMedium    
Sierra Oncology logo
SRRA
Sierra Oncology
11/6/2020Reiterated byLifesci CapitalOutperformLow    
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
11/9/2020Reiterated byLifesci CapitalOutperformLow    
Catalyst Biosciences logo
CBIO
Catalyst Biosciences
11/5/2020Reiterated byLifesci CapitalOutperformHigh    
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
11/5/2020Reiterated byLifesci CapitalOutperformMedium    
InflaRx logo
IFRX
InflaRx
10/30/2020Reiterated byLifesci CapitalMarket PerformLow    
Odonate Therapeutics logo
ODT
Odonate Therapeutics
10/28/2020Reiterated byLifesci CapitalOutperformLow    
OYST
Oyster Point Pharma
10/27/2020Reiterated byLifesci CapitalOutperformMedium    
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
10/23/2020Reiterated byLifesci CapitalOutperformMedium    
Allakos logo
ALLK
Allakos
10/22/2020Reiterated byLifesci CapitalOutperformLow    
MEI Pharma logo
MEIP
MEI Pharma
10/21/2020Reiterated byLifesci CapitalOutperformMedium    
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
10/16/2020Reiterated byLifesci CapitalOutperformLow    
INBX
Inhibrx
10/15/2020Reiterated byLifesci CapitalOutperformMedium    
IMVT
Immunovant
10/6/2020Reiterated byLifesci CapitalOutperformHigh    
VYNE
VYNE Therapeutics
10/2/2020Reiterated byLifesci CapitalOutperformHigh    
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
9/29/2020Reiterated byLifesci CapitalOutperformMedium    
ALXO
ALX Oncology
9/30/2020Reiterated byLifesci CapitalOutperformLow    
CRTX
Cortexyme
9/24/2020Reiterated byLifesci CapitalOutperformHigh    
CSV / Excel Export To export this table to CSV or Excel, upgrade to MarketBeat All Access.

MarketBeat Community Rating for Lifesci Capital

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  10 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  23
MarketBeat's community ratings are surveys of what our community members think about Lifesci Capital and other research firms. Vote "Outperform" if you believe Lifesci Capital's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Lifesci Capital's recmomendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.